Neurocrine Biosciences Reports Q3 Revenue of $1.12B
Q3 revenue was $1.12 billion, compared with a FactSet estimate of $1.04 billion.
Story updates
09:51:07 PM UTC
SquawkNews
Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 BillionINGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 BillionSAN DIEGO, Nov. 2, 2026 // -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter end…
09:54:17 PM UTC
SquawkNews
04:54 PM EST, 11/02/2026 (MT Newswires) -- Neurocrine Biosciences (NBIX) late Monday reported Q3 adj
09:59:06 PM UTC
SquawkNews
Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand Overview